Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.99M | -7.93M | -11.28M | -11.54M | -10.61M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 1.20M | 1.52M | 1.52M | 1.50M | 326.20K |
| Total Other Non-Cash Items | 138.40K | 724.00K | 750.30K | 756.40K | 454.00K |
| Change in Net Operating Assets | -851.30K | -2.86M | -779.10K | -1.29M | -947.10K |
| Cash from Operations | -7.50M | -8.54M | -9.78M | -10.58M | -10.78M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 1.61M | 1.61M | 1.61M | 1.61M |
| Total Debt Repaid | -857.80K | -906.00K | -937.10K | -1.47M | -1.45M |
| Issuance of Common Stock | 4.10M | 3.75M | 2.08M | 8.44M | 9.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.64M | 6.78M | 4.25M | 4.00M | -447.80K |
| Cash from Financing | 9.88M | 11.23M | 7.00M | 12.57M | 8.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.38M | 2.69M | -2.79M | 1.99M | -2.02M |